GSK secures $370 million settlement and future royalties in CureVac mRNA patent dispute

GSK has secured a significant financial settlement and future royalty stream from CureVac, stemming from mRNA patent disputes involving BioNTech and Pfizer. The agreement includes an upfront payment of $370 million ($320M cash) and a 1% royalty on United States sales of Pfizer and BioNTech’s mRNA flu and COVID-19 vaccines from 2025. This deal also reduces GSK's future royalty obligations on its own mRNA vaccines and offers potential for an additional $130 million if BioNTech acquires CureVac, providing GSK with substantial immediate income and a long-term revenue source, despite ongoing separate litigation against Pfizer and BioNTech.

Analysis

GSK has secured a multi-faceted financial victory stemming from its mRNA patent licensing partnership with CureVac. The agreement provides an immediate and material boost to earnings with a $370 million upfront payment, of which $320 million is cash, set to be booked as other operating income in Q3 2025. Beyond the immediate cash infusion, the deal establishes a new, durable revenue stream via a 1% royalty on United States sales of Pfizer and BioNTech's key mRNA vaccines beginning in 2025, effectively monetizing its intellectual property position. Strategically, the revised licensing terms with CureVac also reduce GSK's future royalty burden on its own mRNA pipeline, enhancing the potential profitability of its future vaccine portfolio. This settlement includes a contingent payment of $130 million tied to BioNTech's potential acquisition of CureVac, and importantly, it does not resolve GSK's own direct litigation against Pfizer and BioNTech, meaning this financial gain is secured while preserving the full upside potential from its primary legal challenges in the US and Europe.

Key Decisions for Investors

• Investors should update Q3 2025 models for GSK to include the $370 million in other operating income and view the new 1% royalty as a positive, long-term revenue diversification driver.
• Continue to monitor the progress of GSK's separate, direct litigation against Pfizer and BioNTech, as its outcome represents a potentially much larger, unresolved financial catalyst.
• Investors in Pfizer and BioNTech must account for a new 1% royalty expense on US mRNA vaccine sales from 2025, which sets a negative precedent for other ongoing patent disputes.